In a murine model of HNSCC, a novel NLRP3 inhibitor known as MCC950 demonstrated the ability to delay tumor growth, decrease levels of MDSCs, Tregs, and TAMs, while also enhancing T cell infiltration within the tumor microenvironment (TME). This evidence concerns the gene NLRP3 and neoplasm.